Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARM: Axillary Reverse Mapping in Breast Cancer
NCT03927027Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jul 2019
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer and lymphedema (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Incidence of upper extremity (UE) lymphedema up to 36 months. Started Jul 2019; status: active, not recruiting.
02
Conditions
breast cancerlymphedema
Beyond the preview
Go deeper on NCT03927027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927027.